6 research outputs found

    Las 5Cs de Desarrollo Positivo Juvenil y el Prop贸sito Vital entre Adolescentes de las Minor铆as Roman铆 y Egipcia en Albania

    Get PDF
    The 5Cs model of Positive Youth Development focuses on thriving adolescents who develop positive qualities, which are known to help them deal with challenges, tasks, and psychological concerns. Life Purpose acts as a protective factor in relation to the general well-being of adolescents and supports the 5Cs through this process of growth. The aim of this study is to examine the role of the 5Cs of PYD, namely Competence, Confidence, Connection, Caring, and Character, and how Life Purpose is explained by the 5Cs. There is no precedent study on the 5Cs model of positive youth development in Albania. In specific, this study investigated the 5Cs of PYD for the two most marginalized minority groups in Albania, the Roma, and Egyptian communities. Data were collected from 201 participants from the three most populated cities with Roma minority (N=100) and Egyptian minority (N=101), aged between 14-20 years old. Association between the 5Cs and purpose in life was found. Life Purpose has an association with Character, Caring, and Connection. In interaction with 5Cs, Life Purpose provides a framework for systematic behavior in life by motivating adolescents to plan and make efforts to achieve in decision-making and performance.El modelo de las 5 Cs de Desarrollo Positivo Juvenil se enfoca en adolescentes que desarrollan cualidades positivas, que les ayudan a enfrentarse a los desaf铆os, tareas y preocupaciones psicol贸gicas. El prop贸sito vital act煤a como factor protector en relaci贸n con el bienestar general de los adolescentes y apoya a las 5Cs a trav茅s de este proceso de crecimiento. El objetivo de este estudio es examinar el papel de las 5 Cs de Desarrollo Positivo Juvenil, es decir, Competencia, Confianza, Conexi贸n, Cari帽o y Car谩cter, y c贸mo estas 5 Cs explican el prop贸sito vital. No existe un estudio precedente sobre el modelo 5Cs de desarrollo juvenil positivo en Albania. En concreto, este estudio investig贸 las 5Cs para los dos grupos minoritarios m谩s marginados de Albania, las comunidades roman铆 y egipcia. Se recogieron datos de 201 participantes de las tres ciudades m谩s pobladas con minor铆a roman铆 (N=100) y minor铆a egipcia (N=101), con edades comprendidas entre los 14 y los 20 a帽os. De los 201 participantes, el 53% de las participaciones fueron chicos y el 48% chicas. En cuanto a su estado civil, s贸lo el 12% estaba casado/a. Los hallazgos muestran relaciones significativas entre las 5Cs y su edad, etnia, sexo, niveles de educaci贸n y condiciones de vida. Se encontr贸 una asociaci贸n entre las 5 Cs y el prop贸sito en la vida. El prop贸sito vital tiene una asociaci贸n con el car谩cter, el cari帽o y la conexi贸n. En interacci贸n con las 5Cs, el prop贸sito vital proporciona un marco para el an谩lisis sistem谩tico de la conducta al motivar a los adolescentes a planificar y hacer esfuerzos para lograr una mejor toma de decisiones y desempe帽o

    Irreversible inhibition of 螖16HER2 is necessary to suppress 螖16HER2-positive breast carcinomas resistant to Lapatinib

    No full text
    HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of 螖16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human 螖16HER2 isoform (螖16HER2 mice) develop invasive mammary carcinomas with early onset and 100% penetrance. The present study provides preclinical evidence that 螖16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer. Of note, Dacomitinib, an irreversible small molecule pan-HER inhibitor, was able to completely suppress 螖16HER2-driven breast carcinogenesis. Thus, only Dacomitinib may offer benefit in this molecularly defined patient subset by irreversibly inhibiting 螖16HER2 activation
    corecore